Bevespi Aerosphere approved in China for patients with COPD
LONDON: AstraZeneca’s Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in China as a maintenance treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. The approval by the National Medical Products Administration (NMPA) was based on positive results from the Phase III PINNACLE 4 trial in which Bevespi…